NSAIDs are one of the most commonly used
groups of medications worldwide. Apart from
the well-documented toxicity to the upper gas-
trointestinal tract, these medications are now
known to cause serious enteropathy of the small
bowel. NSAID-induced enteropathy is fre-
quently overlooked by clinicians because of its
vague presentation. Up to 70% of patients taking
NSAIDs long term may have asymptomatic
enteropathy of the small bowel.
1
Pathogenesis
NSAID-induced enteropathy appears to be a
multi-stage process involving increased intesti-
nal permeability, loss of function in the intestinal
barrier resulting in bacterial invasion, and an
Cases
Meloxicam-induced enteropathy of the small bowel
Chaitanya Are MBBS, Mohit Turagam MBBS, John A. Aucar MD MSHI, Eugene Greenberg MD
Competing interests:None
declared.
This article has been peer
reviewed.
Correspondence to:
Dr. Chaitanya Are,
[email protected]
CMAJ 2011. DOI:10.1503
/cmaj.091748
PracticeCMAJ
• Up to 70% of patients taking nonsteroidal anti-inflammatory drugs
(NSAIDs) may have asymptomatic enteropathy.
• Small-bowel lesions (mucosal tears and ulcers) from NSAID-induced
enteropathy are an important cause of occult gastrointestinal blood
loss.
• The formation of diaphragm-like strictures in the small bowel should
be considered in the differential diagnosis of otherwise unexplained
chronic abdominal pain and intestinal obstruction in patients taking
NSAIDs.
• The mainstay of treatment is to stop NSAID use.
Key points
© 2011 Canadian Medical Association or its licensors CMAJ, March 22, 2011, 183(5) 577
case-are_Layout 1 02/03/11 11:39 AM Page 577
inflammatory tissue reaction.1 NSAIDs uncouple
mitochondrial oxidative phosphorylation, which
reduces the intracellular levels of adenosine
triphosphate in the enterocyte. This in turn re -
duces the integrity of intercellular junctions and
increases intestinal permeability. As a result of
the increased permeability, intestinal mucosa is
susceptible to damage from luminal contents
such as bile acids, hydrolytic and proteolytic
enzymes, and bacteria. The damage to the mu -
cosa triggers an inflammatory response, with
production of inflammatory cytokines and neu-
trophil infiltration. Release of lysosomal en -
zymes from neutrophils results in tissue damage
in the form of ulceration. The development of
ulcers and the subsequent reparative process is
thought to result in diaphragm-like strictures.
1,2
Prostaglandin synthesis from arachidonic acid
by the damaged cells is decreased secondary to
the inhibition of cyclo-oxygenase (COX) by
NSAIDs. This effect further increases the dam-
age caused by the inflammatory response.
Recent studies have shown that both isoforms of
the COX enzyme (COX-1 and COX-2) play a
role in maintaining mucosal integrity of the
small intestine.
3 The microcirculatory dysfunc-
tion and increase in intestinal motility noted with
the use of NSAIDs may also play a contributory
role in the development of NSAID-induced
enteropathy.
3
Complications
NSAID-induced enteropathy often goes unde-
tected because patients are asymptomatic. In -
creased intestinal permeability has been reported
to occur as early as 12 hours after a single dose
of most conventional NSAIDs.
2 The spectrum of
NSAID-induced enteropathy is summarized in
Box 1.
How long clinically significant disease takes
to develop is unclear. Protein loss due to
enteropathy can result in clinically significant
hypoalbuminemia. Chronic occult blood loss
from mucosal tears and ulcerations can lead to
iron deficiency anemia, as noted in our patient.
The diaphragm-like strictures that form after the
ulcers heal may cause patients to experience
nausea, vomiting, colicky abdominal pain,
intestinal obstruction and even perforation.
Diagnosis
The diagnosis of NSAID-induced enteropathy
requires awareness of the potential toxic effects
of NSAIDs. Often endoscopy of the upper gas-
trointestinal tract and colonoscopy do not show
abnormal mucosal findings because the lesions
may be predominantly located in the small intes-
tine. Factors that help establish the diagnosis
include typical endoscopic findings of erosions,
tears, ulcers or typical diaphragm-like strictures,
along with improvement in clinical and endo-
scopic findings after the NSAID is stopped.
Video capsule endoscopy and double-balloon
endoscopy supplement endoscopy of the upper
and lower gastrointestinal tracts in visualizing
the small bowel. Direct visualization helps to
rule out other causes such as inflammatory
bowel disease and cancer. The diagnostic yield
of video capsule endoscopy and double-balloon
endoscopy in the evaluation of the small bowel
for occult bleeding, inflammatory findings and
tumour detection was not found to differ sub-
stantially.
4 However, cost-effectiveness favours
video capsule endoscopy over push enteroscopy
and radiologic studies in the diagnosis of obscure
bleeding.4
The potential complications of video capsule
endoscopy are retention of the capsule and
obstruction, especially in the presence of stric-
tures. The complications could be reduced with
Practice
578 CMAJ, March 22, 2011, 183(5)
Figure 1: Images from video capsule endoscopy of the small bowel in a 52-year-old woman with meloxicam-induced enteropathy,
showing inflammation and erosion of mucosa (white arrows) and diaphragm-like strictures resulting in various degrees of luminal nar-
rowing (black arrows).
case-are_Layout 1 02/03/11 11:39 AM Page 578
use of the patency capsule. The patency capsule
is the same size as the video capsule and consists
of a small radio frequency identification tag en -
closed in a lactose capsule. When retained in the
intestine for more than 30 hours, the lactose cap-
sule disintegrates, leaving behind the tag. Pat -
ency of the intestinal lumen is determined by
passage of an intact capsule or the absence of a
signal from the tag in the body after 30 hours.4
Radiologic studies can help establish a diag-
nosis, but they often yield false-negative results.
The diaphragm-like strictures may be misinter-
preted as exaggerated plicae circulares, and
contrast studies are not sensitive for detecting
mucosal lesions.
Other tests include the indium-labelled leuko-
cyte technique and single-stool fecal calprotectin
excretion. Even though these tests have been val-
idated for identifying inflammation associated
with NSAID-induced enteropathy, they are lim-
ited by their lack of specificity.
2
Prevention
Effective strategies to prevent NSAID-induced
enteropathy are not available. The results of pro-
phylaxis with misoprostol have been variable
and dose dependent, with high doses associated
with significant gastrointestinal side effects.
5
Reduction in gastric acid secretion does not play
an important role in prevention.1 As noted in our
patient, concurrent use of omeprazole did not
prevent the NSAID-induced enteropathy.
Rebamipide, a new mucosal protective agent
not currently available in Canada or the United
States, enhances mucosal defence by scavenging
free radicals and temporarily activating genes
encoding the COX-2 enzyme. In a study involv-
ing healthy volunteers, rebamipide was found to
be significantly more efficacious than placebo in
preventing NSAID-induced injury to the mucosa
of the small intestine.
6
Treatment
The mainstay of treatment is to stop NSAID use.
Switching from one NSAID to another does not
offer any benefit, because enteropathy has been
reported with most conventional NSAIDs, in -
cluding acetylsalicylic acid.
2,7
Despite an initial report that COX-2 inhibitors
produced no change in intestinal permeability in
healthy volunteers,8 a recent study noted small-
bowel injury in up to 50% of patients taking COX-
2–selective agents for three months or longer.9 No
statistically significant difference in the prevalence
of small-bowel injury was noted between patients
taking COX-2–selective agents and those taking
conventional NSAIDs.
9
Even though long-term concurrent use of
misoprostol may not prevent the development
of enteropathy, it does reduce intestinal inflam-
mation in patients with established NSAID-
induced enteropathy and lessens the severity of
the disease.
1
The reduction in intestinal inflammation and
blood loss reported with the use of metronidazole
has been attributed to the antibacterial properties
of the drug and the role of bacterial invasion in
NSAID-induced enteropathy.
10 Another probable
mechanism underlying the protective effect of
metronidazole is the reduction in the degree of
uncoupling of mitochondrial oxidative phospho-
rylation induced by NSAIDs.1
Sulfasalazine is another drug reported to
reduce intestinal inflammation and blood loss. 1,2
However, these results were from small pilot
studies and require careful interpretation.
Although the mucosal erosions and ulcers
improve after NSAIDs are stopped, the effect on
the diaphragm-like strictures is unclear. When
symptoms persist despite medical therapy, sur -
gery may be necessary, and the diagnosis is
often made at laparotomy.